Our findings regarding phase II genes are consistent with results from several case-control studies which have previously reported an association between polymorphisms in NAT, GSTM and GST and various types of cancer [19,38-43,55,56] or coronary heart disease [44,45]. The gene discussed is BRD2; the disease is coronary artery disorder.